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Abstract
Background: The demand on antigen binding reagents in research, diagnostics and therapy raises
questions for novel antibody formats as well as appropriate production systems. Recently, the
novel single chain Fab (scFab) antibody format combining properties of single chain Fv (scFv) and
Fab fragments was produced in the Gram-negative bacterium Escherichia coli. In this study we
evaluated the Gram-positive bacterium Bacillus megaterium for the recombinant production of
scFab and scFvs in comparison to E. coli.
Results: The lysozyme specific D1.3 scFab was produced in B. megaterium and E. coli. The total yield
of the scFab after purification obtained from the periplasmic fraction and culture supernatant of E.
coli was slightly higher than that obtained from culture supernatant of B. megaterium. However, the
yield of functional scFab determined by analyzing the antigen binding activity was equally in both
production systems. Furthermore, a scFv fragment with specificity for the human C reactive
protein was produced in B. megaterium. The total yield of the anti-CRP scFv produced in B.
megaterium was slightly lower compared to E. coli, whereas the specific activity of the purified scFvs
produced in B. megaterium was higher compared to E. coli.
Conclusion: B. megaterium allows the secretory production of antibody fragments including the
novel scFab antibody format. The yield and quality of functional antibody fragment is comparable
to the periplasmic production in E. coli.
Background
Recombinant antibody fragments are indispensible tools
for research, diagnostics and therapy [1-3]. However, new
areas of application and the increasing demand for recom-
binant antibodies requires new antibody formats as well
as appropriate production systems. Particularly, if a large
number of different antibody clones must be produced,
for example for the functional genome analysis, bacteria
are a very interesting antibody production system,
because they offer simple medium demands, short pro-
duction time and high capacity to produce recombinant
proteins. However, the capability to produce functional
full-size antibodies in bacteria is very limited. Therefore,
smaller antibody fragments like the single chain Fv (scFv)
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and Fab are produced in bacteria. The scFv format is com-
posed of the variable regions of the antibody heavy (VH)
and the light chain (VL) linked by a 15–25 amino acid
linker [4,5]. ScFvs have the tendency to form aggregates
and are relatively unstable over longer periods of time [6].
Furthermore, some scFvs show a reduced affinity of up to
one order of magnitude compared to the corresponding
Fab fragments [7]. Only in rare cases scFvs with a higher
affinity than the associated Fab have been found [8]. Fab
fragments are composed of VH and VL fused to the follow-
ing constant antibody domain of the heavy (CH1) and
light chain (CL). Both chains are covalently linked by a
disulphide bridge. Because they are double the molecular
size, and require the production and connection of two
different polypeptides with a disulphide bond, folding
and assembly of Fab fragments in the periplasm of E. coli
is less efficient than of scFvs [9]. A further disadvantage of
Fab fragments is the tendency of the light chains to form
homo-dimers, which are known as Bence Jones proteins
[10]. Advantages of Fab fragments are their high stability
while long term storage [11] and their compatibility with
common detection antisera without the need for a re-
engineering step [2]. Recently, the novel single chain Fab
(scFab) antibody format was developed by Hust et al. [12]
combining the advantages of scFv and Fab fragments. The
scFab is composed of VH-CH1 and VL-CL connected by
an 34 amino acid linker without the cysteins connecting
both antibody chains (scFab∆C). The scFab was produced
functionally in E. coli and Pichia pastoris [12].
Due to the lack of the outer membrane Gram positive bac-
teria have higher capacity for protein secretion into the
medium in comparison to Gram negative E. coli. The
Gram-positive bacteria B. brevis [13,14] and B. subtilis
[15,16] have already been successfully used for the pro-
duction of antibody fragments. In contrast to B. subtilis, B.
megaterium does not produce alkaline proteases and has
also a higher plasmid stability during growth [17], a pre-
requisite for stable gene expression in long term cultiva-
tions like in bioreactors. Recently, the first production of
functional lysozyme specific scFv (D1.3) antibody frag-
ments in B. megaterium was successfully demonstrated
[18]. In this study, B. megaterium was used for the produc-
tion of the novel scFab format and another scFv fragment
and compared to E. coli production of the same antibody
fragments.
Results
Construction of the vectors pEJBmD1.3scFab and 
pEJBmLA13-IIE3scFv
The anti-lysozyme scFab D1.3 (scFab∆C) DNA was ampli-
fied using polymerase chain reaction (PCR) from the vec-
tor pHAL1-D1.3-scFab∆C [12] using gene specific
oligonucteotide primers and cloned between the restric-
tion sites NheI and NotI of pEJBmopSplipA [18] resulting
in the vector pEJBmD1.3scFab (Fig. 1). In the same way,
the anti human C-reactive protein (CRP) scFv LA13-IIE3
obtained by phage display (Al-Halabi et al., unpublished)
was amplified using gene specific oligonucleotide primer
and cloned into pEJBmopSplipA [18].
Production and analysis of D1.3 scFab in B. megaterium 
and E. coli
The D1.3 scFab was produced in B. megaterium in shaking
flask for 24 h after induction with xylose. Samples were
taken from the supernatant after 0 h, 6 h and 24 h after
induction were ammonium sulfate precipitated and aliq-
uots were analysed by SDS-PAGE and immunoblot (Fig.
2A) and ELISA on lysozyme (Fig. 2B). After 6 hours of pro-
duction first scFab were detected by immunostaining,
whereas almost no specific activity was determined by
ELISA. Best production and function was observed after
24 hrs.
For purification, the supernatant of the D1.3 scFab pro-
duction in B. megaterium was precipitated using ammo-
Plasmid map of pEJBmD1.3scFab Figure 1
Plasmid map of pEJBmD1.3scFab. Abbreviations: bla: β-lacta-
mase gene for ampicillin resistance; colE1: E. coli origin of 
plasmid replication; His-tag: synthetic 6xhistidine tag; ori: B. 
megaterium origin of plasmid replication; PxylA: xylose induci-
ble promoter; RBS: ribosome binding site; repU: a gene for 
plasmid replication in B. megaterium; scFab: single chain frag-
ment antigen binding; SPlipA: signal peptide sequence of B. 
megaterium extracellular esterase LipA; terminator: sequence 
terminating transcription; tet: tetracyclin resistence gene; LC: 
light chain; Fd: VH and CH1 of the heavy chain; xylR: xylose 
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nium sulfate and the resolved pellet was purified by
immobilized metal affinity chromatography (IMAC) (Fig.
3A). For comparision, the D1.3 scFab produced in E. coli
was isolated from both the periplasmic space and the
medium supernatant. In total, 3,5 µg/L scFab D1.3 were
isolated from B. megaterium and 9,5 µg/L scFab were iso-
lated from E. coli. The specific activity of the D1.3 scFab
produced in both production hosts were compared by
ELISA on antigen (Fig. 3B). The specific activity deter-
mined by ELISA of the purified scFab was similiar for both
production systems.
Production and analysis of the anti-CRP scFv in Bacillus 
megaterium
To verify the results of the D1.3 scFv production in B. meg-
aterium [18], an anti-CRP scFv was produced in B. megate-
rium. The scFv was purified from the precipitated
supernatant using IMAC (Fig. 4A). In parallel, the anti-
CRP scFv was produced in E. coli. In total, 390 µg/L anti-
CRP scFv were isolated from Bacillus megaterium and 550
µg/L anti-CRP scFv were isolated from E. coli. The specific
activity of the LA13-IIE3 scFv produced in both produc-
tion hosts were compared by ELISA on antigen (Fig. 4B).
The specific activity of the scFv was higher when produced
in B. megaterium.
Discussion
The Gram-negative bacterium E. coli is the best character-
ized bacterial production host and is a well established
production host for recombinant antibody fragments. The
yield strongly depends on the individual antibody and the
production system, e.g. shake flask or fermenter, e.g. 300
Analysis of functional anti-lysozyme D1.3 scFab after 0, 6 and 24 h of production Figure 2
Analysis of functional anti-lysozyme D1.3 scFab after 0, 6 and 24 h of production. A Ammonium sulfate precipated scFabs from 
0.75 mL supernatant were separated by reducing SDS-PAGE (10%) and detected using mAb mouse anti-His and goat anti-
mouse IgG AP (Fc specific). B Antigen binding ELISA with 50 µL culture supernatant from a production in 100 mL scale. Mean 
values and standard deviations of data obtained from three different experiments are given. Antigens: 1 µg/well lysozyme or 1 
µg/well control protein BSA. The D1.3 scFabs were detected using mAb mouse anti-His and goat anti-mouse IgG HRP (Fc spe-
cific).
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µg/L were reported for an anti scorpion toxin scFv in shake
flask [19], but up to 2.5 g Fab fragments/L were obtained
from high cell fermentation [20]. In E. coli, the correct for-
mation of disulphide bonds, a prerequisite for functional
antibodies and antibody fragments, is only possible in the
oxidizing environment of the perisplamic space. There-
fore, the produced antibody fragments have to be isolated
from the periplasm, so usually only a fraction accumu-
lates in the medium supernatant. But in many cases anti-
body fragments can be isolated from the medium
supernatant [21-23]. The advantage of Gram-positive bac-
teria is the lack of the outer membrane. Hence, all pro-
duced antibody fragments can directly be harvested from
the medium supernatant. Gram-positive bacteria already
have been succesfully used for the production of antibody
fragments, like B. subtilis [15,16], B. brevis [13,14] and very
recently,  B. megaterium [18] was shown to be able to
secrete functional scFv fragments.
Here, a new antibody format, the scFab, was produced in
B. megaterium to analyse the capability of this production
system to assemble more complex antibody fragments
with a higher molecular weight. Functional anti-lysozyme
D1.3 scFabs were successfully produced using B. megate-
rium. The total amount of the scFab was significantly
lower compared to the production of the corresponding
scFv fragment [18]. This was expected due to the double
molecular size and double amount of disulphide bonds
of the scFab. Additionally, the scFab was produced in E.
coli to compare the yield and the specific activity. The total
yield of the production in B. megaterium is lower than in
E. coli. Whereas, the specific activity of the purified scFab
Purification and analysis of anti-lysozyme D1.3 scFabs Figure 3
Purification and analysis of anti-lysozyme D1.3 scFabs. A Westernblot and immunostain of the combined supernatan of 6 inde-
pendent productions, wash fractions and elution fractions of the IMAC purification. Samples were separated by reducing SDS-
PAGE (12%) and detected using mAb mouse anti-His and goat anti-mouse IgG AP (Fc specific). B Antigen binding ELISA of 
purified scFab produced in B. megaterium or E. coli, performed as described in figure 2.
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produced in B. megaterium is comparable to E. coli. B. meg-
aterium is next to E. coli and P. pastoris the third production
host which was shown to be suitable for the production of
scFabs.
Consequently, the production of another scFv, an anti-
CRP scFv LA13-IIE3, was analysed. The scFv LA13-IIE3
was produced in similar amounts compared to D13 scFv
in B. megaterium. The total amount of purified LA13-IIE3
was slightly higher in E. coli. However, the specific activity
of the scFv produced in B. megaterium was higher when
compared to the E. coli production. A similiar difference
was observed before for the anti-lysozyme antibody D1.3
[18].
E. coli production systems were optimized for the produc-
tion of heterologous proteins for more than two decades
[24] and used for the expression of recombinant antibod-
ies since 1988 [4,5,25]. The new production host B. meg-
aterium  has to be optimized for the production of
antibodies to increase the yield. The highest production
yields of E. coli were reached using high cell fermentation,
e.g. Chen et al. [20]. Fermentation of B. megaterium for the
production of non heterologous proteins was shown, e.g.
Sindhu et al. [26]. Because of the higher stability of plas-
mids in B. megaterium compared to B. subtilis during
growth, B. megaterium may well be better suited for the
production of recombinant proteins in fermenters [17].
Purification and analysis of anti-CRP LA13-IIE3 scFvs Figure 4
Purification and analysis of anti-CRP LA13-IIE3 scFvs. A Westernblot and immunostain of the combined supernatant of 3 inde-
pendent productions, wash fractions and elution fractions of the IMAC purification. Samples were separated by reducing SDS-
PAGE (12%) and detected as described in figure 3. B Antigen binding ELISA of purified anti-CRP scFv produced in B. megaterium 
or E. coli. Antigens: 100 ng/well CRP or 100 ng/well control protein BSA, detection as described in figure 2.
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In conclusion, the production host B. megaterium offers an
alternative to E. coli for the production of recombinant
antibody fragments which has to be further evaluated.
Conclusion
B. megaterium is able to produce more complex antibody
formats like the novel scFab. It shows less total productiv-
ity but similiar product quality compared to E. coli. In
comparision to E. coli, B. megaterium production is still
not very well examined and need further optimisation.
Methods
Transformation of B. megaterium
Transformations of non-sporulating B. megaterium strain
MS941 [27] were performed as described by Barg et
al.[28].
Production and export of scFab and scFv using B. 
megaterium
The anti-lysozyme scFab D1.3 and anti-CRP scFv LA13-
IIE3 were produced in 500 mL shaking flasks. 3 × 100 mL
TB medium + 10 µg/mL tetracycline [29] for scFv LA13-
IIE3 or 6 × 100 mL for scFab D1.3 were inoculated with 1
mL overnight culture at 37°C and 250 rpm. The induction
was started by adding 0.5% xylose at O.D.600 nm = 0.3 –
0.4. The cultures were grown at 250 rpm and 41° for 24.
The supernatant was directly used for ELISA. For SDS-
PAGE analysis and protein purification the proteins of the
supernatant were precipitated using 440 g/L ammonium
sulfate.
Production of scFab and scFv in E. coli
The anti-lysozyme scFab D1.3 and anti-CRP scFv LA13-
IIE3 were produced in 1 L shaking flasks using the vector
pOPE101 [30] and the E. coli strain XL1-Blue MRF' (Strat-
agene, Amsterdam, Netherland). Briefly, 300 mL 2 × TY +
100 mM glucose + 100 µg/mL ampicillin were inoculated
with an overnight culture yield to O.D.600 nm = 0.1 and cul-
tured at 37°C and 250 rpm. The scFv and scFab produc-
tion was induced by adjusting to 50 µM isopropyl-beta-D-
thiogalacto-pyranoside (IPTG) at O.D.600 nm = 0.5 and
shaking for 3 h at 30°C. Bacteria were harvested by 15
min at 4225 × g and 4°C. The supernatant was used for
ammonium sulfate precipitation (see below). Bacteria
pellets were resuspended in 1/10 culture volume ice cold
PE buffer, pH 8 (20% sucrose, 50 mM Tris, 1 mM EDTA)
and incubated for 20 min on ice, interrupted by short vor-
texing every 2 min. Subsequently the bacteria were pel-
leted for 30 min at 30,000 × g and 4°C. The supernatant
(periplasmic fraction) was stored at -20°C. The remaining
supernatant from the first bacteria centrifugation was pre-
cipated using 440 g/L ammonium sulfate, stirred 1 h at
4°C and centrifuged for 30 min at 13689 × g and 4°C. The
protein pellet was dissolved in 35 mL/L culture phosphate
buffered saline (PBS) [29]. The periplasmic fraction and
the precipitated supernatant were combined and dialysed
over night against PBS at 4°C.
Immobilized metal affinity chromatography (IMAC) 
purification of antibody fragments
Antibody fragments were purified from E. coli or B. mega-
terium derived material by affinity chromatography using
IMAC. Chromatography using 0.5 mL Chelating Sepha-
rose Fast Flow (GE Healthcare, Munich, Germany) was
performed according to the manufacturers' instruction.
The protein solution was adjusted to 10 mM imidazol
containing buffer pH7.4 (20 mM Na2HPO4, 500 mM
NaCl, 10 mM imidazol) for loading. The column was
washed once with 10 mM imidazol, once with 20 mM for
scFv purification or with 50 mM for scFab purification,
then once with 50 mM imidazol buffer and once with
PBS. The elution was done in three steps, twice elution
with 20 mM Na2HPO4, 500 mM NaCl and 250 mM imi-
dazol and finally PBS with 100 mM EDTA were used for
the elution.
Antigen binding ELISA
Maxisorb MTPs (Nunc, Wiesbaden, Germany) were
coated with either 1 µg hen egg white lysozyme, 100 ng
CRP (BiosPacific, Emeryville, California) or BSA as con-
trol protein in 100 µL PBS per well overnight at 4°C.
Coated wells were washed three times with PBST (PBS +
0,1% (v/v) Tween 20) and blocked with 2% (w/v) skim
milk powder (Roth, Karlsruhe, Germany) in PBST for 1.5
h at RT, followed by three times washing with PBST. Sol-
uble antibody fragments were diluted in 100 µL blocking
solution and incubated for 1.5 h, followed by three times
washing with PBST. Soluble antibody fragments were
detected with mAb mouse anti-penta His-tag (1:10000)
(Qiagen, Hilden, Germany) and polyclonal goat anti-
mouse IgG (Fc specific) conjugated with horseradish per-
oxidase (HRP) (1:10000) (Sigma, Taufkirchen, Germany)
and visualised with 100 µL TMB (3,3',5,5'-tetramethyl-
benzidine) substrate. The staining reaction was stopped
by adding 100 µL 1 N sulphuric acid. The absorbance at
450 nm subtracted by the absorbance of scattered light at
620 nm were measured using a microtitre plate reader
SUNRISE (Tecan, Crailsheim, Germany).
SDS-PAGE and Immunoblot
Soluble antibody fragments were separated by SDS-PAGE
[31] and blotted onto polyvinylidene fluoride (PVDF)
membrane (Millipore, Schwalbach, Germany). The mem-
brane was blocked with 3% (w/v) skim milk powder in
PBS for 30 min at RT. For the detection of soluble anti-
body fragments the mAb mouse anti-penta His-tag
(1:2000) was used as first antibody and goat anti-mouse
IgG (Fc specific) conjugated with alkaline phosphatase
(AP) (Sigma, Taufkirchen, Germany) (1:5000) was usedMicrobial Cell Factories 2007, 6:38 http://www.microbialcellfactories.com/content/6/1/38
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as second antibody. The blot was visualised using NBT/
BCIP substrate reaction.
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